Abstract: Novel, lubricious coatings for medical devices are disclosed. The coatings provide improved lubricity and durability and are readily applied in coating processes a low temperatures that do not deform the device. The present invention is also directed to a novel platinum catalyst for use in such coatings. The catalyst provides for rapid curing, while inhibiting cross-linking at ambient temperatures, thereby improving the production pot life of the coatings.

Abstract: There is provided a method and apparatus for identifying malicious code. The method uses machine learning to compare a new code segment to known code segments of malicious code. Code segments are converted to vectors and the cosine similarity of two vectors is used to identify clones. Techniques to train a neural network for handling very long code sequences and obfuscated malicious code are used.

Abstract: Various aspects of the present disclosure generally relate to wireless communication. In some aspects, a user equipment (UE) may transmit, to a network node, a polarization performance loss indication that is indicative of a loss in polarization performance based on transitioning from a first operating state associated with a first frequency range to a second operating state associated with a second frequency range, wherein the first operating state corresponds to a first antenna configuration and the second operating state corresponds to a second antenna configuration, wherein the first antenna configuration corresponds to a first antenna orientation and the second antenna configuration corresponds to a second antenna orientation. The UE may receive, from the network node, configuration information indicative of at least one communication parameter associated with the at least one antenna array and based on the polarization performance loss indication. Numerous other aspects are described.

Abstract: Embodiments of a recombinant human Parainfluenza Virus (hPIV) F ectodomain trimer stabilized in a prefusion conformation are provided. Also disclosed are nucleic acids encoding the hPIV F ectodomain trimer and methods of producing the hPIV F ectodomain trimer. Methods for inducing an immune response in a subject are also disclosed. In some embodiments, the method can be a method for treating or inhibiting a hPIV infection in a subject by administering a effective amount of the recombinant hPIV F ectodomain trimer to the subject.

Abstract: Various aspects of the present disclosure generally relate to wireless communication. In some aspects, a network node may communicate, using a first set of active antenna elements of an antenna array, during a first time period. The network node may activate a second set of active antenna elements based on a dynamic antenna set switching scheme, wherein the second set of active antenna elements includes at least one active antenna element not included in the first set, wherein a difference between a first main lobe property and a second main lobe property satisfies a main lobe threshold, and wherein a difference between a first side lobe property and a second side lobe property satisfies a side lobe threshold. The network node may communicate, using the second set of active antenna elements, during a second time period. Numerous other aspects are described.

Abstract: Various aspects of the present disclosure generally relate to wireless communication. In some aspects, a network node may communicate, using a first set of active antenna elements of an antenna array, during a first time period. The network node may activate a second set of active antenna elements based on a dynamic antenna set switching scheme, wherein the second set of active antenna elements includes at least one active antenna element not included in the first set, wherein a difference between a first main lobe property and a second main lobe property satisfies a main lobe threshold, and wherein a difference between a first side lobe property and a second side lobe property satisfies a side lobe threshold. The network node may communicate, using the second set of active antenna elements, during a second time period. Numerous other aspects are described.

Abstract: Embodiments of a recombinant Respiratory Syncytial Virus (RSV) F ectodomain trimer stabilized in a prefusion conformation are provided. Also disclosed are nucleic acids encoding the RSV F ectodomain trimer and methods of producing the RSV F ectodomain trimer. Methods for inducing an immune response in a subject are also disclosed. In some embodiments, the method can be a method for treating or preventing a RSV infection in a subject by administering a therapeutically effective amount of the recombinant RSV F ectodomain trimer to the subject.

Abstract: Compositions and methods for Cas-based ex vivo and in vivo gene therapy applications are provided.

Abstract: A method of making an implantable prosthesis includes applying a gelling enhancer layer over an inner surface of a wall of a silicone shell having anterior and posterior walls surrounding an interior volume. The method includes filling the interior volume of the shell with a silicone gel and curing the silicone gel. The cured silicone gel that is located within a zone that is in the vicinity of the gelling enhancer layer has a higher level of cohesiveness than the cured silicone gel that is located outside the zone. The zone of the silicone gel having the higher level of cohesiveness has a thickness of 2-10 mm. The silicone gel located outside the zone has a first concentration level of a gelling enhancer and the silicone gel located within the zone has a second concentration level of the gelling enhancer that is 5%-300% greater than the first concentration level.

Abstract: Embodiments of a recombinant human Parainfluenza Virus (hPIV) F ectodomain trimer stabilized in a prefusion conformation are provided. Also disclosed are nucleic acids encoding the hPIV F ectodomain trimer and methods of producing the hPIV F ectodomain trimer. Methods for inducing an immune response in a subject are also disclosed. In some embodiments, the method can be a method for treating or inhibiting a hPIV infection in a subject by administering a effective amount of the recombinant hPIV F ectodomain trimer to the subject.

Abstract: A novel two-step process for batch coating surgical needles with cross-linked silicone coatings is disclosed. The surgical needles are cured using a two-step process. The coatings on the needles are partially cured in the first step and mechanically separated. The coatings on the needles are then fully cured in the second step.

Abstract: Systems and methods for coating surgical needles are provided.

Abstract: Novel, lubricious coatings for medical devices are disclosed. The coatings provide improved lubricity and durability, and are readily applied in coating processes. The present invention is also directed to a novel platinum catalyst for use in such coatings. The catalyst provides for rapid curing, while inhibiting cross-linking at ambient temperatures, thereby improving the production pot life of the coatings.

Abstract: Recombinant Norovirus Virus-Like Particles (VLPs) formed from recombinant Norovirus VP1 proteins, and methods of their use and production are disclosed. In several embodiments, the Recombinant Norovirus VLPs can be used to generate an immune response to Norovirus VP1 protein in a subject. In additional embodiments, an effective amount of the recombinant Norovirus VLPs can be administered to a subject in a method of inhibiting a Norovirus infection.

Abstract: A blackened surgical needle made by the method of treating blackened surgical needles, comprising the steps of: a. determining that a blackening process may have produced loose black oxide particles on the blackened surgical needle; b. placing at least one blackened surgical needle having loose black oxide particles on its surface into a bath, wherein the bath comprises: i. an effective amount of citric acid to remove loose black oxide particles from the at least one blackened surgical needle; and ii. a source of ultrasound; and c. applying the ultrasound in the bath for a time sufficient to remove loose black oxide particles from the surface of the at least one needle and wherein the contents of the bath are maintained at a pH below 3.25.

Abstract: The disclosure provides for vectors encoding a fusion polypeptide comprising a modified hexosaminidase beta-subunit that forms homodimers, a linker and an ApoE peptide that allows for transport across the blood brain barrier, the encoded polypeptide, and methods of using the vector or polypeptide.

Abstract: Novel compositions and systems for closure of wounds are disclosed. The compositions provide devices of improved flexibility and elasticity and are readily applied to wound sites or over wound closure devices. The present invention is also directed to a novel platinum catalyst for use in such compositions. The catalyst provides for rapid curing on topical surfaces such as skin and bonds to such surfaces in about 2-5 minutes.

Abstract: Embodiments of immunogens based on the HIV-1 Env fusion peptide and methods of their use and production are disclosed. Nucleic acid molecules encoding the immunogens are also provided. In several embodiments, the immunogens can be used to generate an immune response to HIV-1 Env in a subject, for example, to treat or prevent an HIV-1 infection in the subject.

Abstract: Nucleases and methods of using these nucleases for inserting a sequence encoding a therapeutic IDUA or IDS protein such as an enzyme into a cell, thereby providing proteins or cell therapeutics for treatment and/or prevention of MPS I or MPS II disease.

Abstract: Novel methods for producing porous silicone compositions are disclosed. Methods of this invention provide improved processes for preparing porous silicone rubbers having low specific gravity and mainly closed cells which are suitable for highly permeable gas penetration while adequately sealing liquid material. Examples of these sealing materials include but are not limited to encapsulants for bioindicators and syringe sealing components wherein the permeability is sufficient to permit sterilization while preventing passage or leaking of liquids to be sterilized through the described silicone materials.